Calidi Biotherapeutics, Inc. (CLDI)

NYSEAMERICAN: CLDI · IEX Real-Time Price · USD
0.589
+0.021 (3.75%)
Mar 28, 2024, 9:56 AM EDT - Market open
3.75%
Market Cap 34.43M
Revenue (ttm) n/a
Net Income (ttm) -29.22M
Shares Out 35.54M
EPS (ttm) -1.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,557
Open 0.610
Previous Close 0.568
Day's Range 0.589 - 0.613
52-Week Range 0.482 - 13.790
Beta 0.42
Analysts Strong Buy
Price Target 3.25 (+451.78%)
Earnings Date Mar 15, 2024

About CLDI

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic include... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 41
Stock Exchange NYSEAMERICAN
Ticker Symbol CLDI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for CLDI stock is "Strong Buy." The 12-month stock price forecast is $3.25, which is an increase of 451.78% from the latest price.

Price Target
$3.25
(451.78% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results

SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results.

12 days ago - Business Wire

Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer

SAN DIEGO & LOS ANGELES--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics and City of Hope Announce Funding from CIRM to Advance CLD-101 (NeuroNova) in Ovarian Cancer.

17 days ago - Business Wire

Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference

SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conferen...

6 weeks ago - Business Wire

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board.

2 months ago - Business Wire

Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit

SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Sum...

3 months ago - Business Wire

Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results

SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results.

4 months ago - Business Wire

Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023)

SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at SITC 2023.

5 months ago - Business Wire

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on September 12, 2023

7 months ago - GlobeNewsWire

First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments

Business combination transaction with Calidi Biotherapeutics anticipated to be completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics from transaction will total appro...

7 months ago - GlobeNewsWire

FIRST LIGHT ACQUISITION GROUP, INC. Further Adjourns Special Meeting of Stockholders to August 28, 2023 at 10:30 am ET

NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE: FLAG) (“FLAG”) today announced that it reconvened and then further adjourned, without conducting any other busine...

7 months ago - GlobeNewsWire

FIRST LIGHT ACQUISITION GROUP, INC. Adjourns Special Meeting of Stockholders to August 24, 2023 at 10:30 am ET

NEW YORK, Aug. 22, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE: FLAG) (“FLAG”) today announced that it convened and then adjourned, without conducting any other business, its vi...

7 months ago - GlobeNewsWire

Flag Stockholders: Reminder to Vote for Proposed Business Combination

RESTON, Va, Aug. 16, 2023 (GLOBE NEWSWIRE) -- irst Light Acquisition Group, Inc. (“FLAG”) (NYSE American: FLAG), a special purpose acquisition company, reminds FLAG stockholders that the FLAG Board of...

8 months ago - GlobeNewsWire

First Light Acquisition Group, Inc. Announces Effectiveness of Registration Statement and Sets August 22, 2023 as Date of Stockholder Meeting for the Calidi Business Combination

RESTON, Va., Aug. 07, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (“FLAG”) (NYSE American: FLAG), a special purpose acquisition company, today announced that the U.S. Securities and E...

8 months ago - GlobeNewsWire

Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer

Financing led by Jackson Investment Group (JIG) with participation from Calidi Cure, LLC, a consortium of new and existing investors led by Allan Camaisa, CEO and Chairman of Calidi Biotherapeutics, a...

9 months ago - GlobeNewsWire

Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies

-Total gross proceeds from transaction, before payment of transaction expenses, expected to be up to $82 million assuming no redemptions, combining a possible PIPE financing of up to $40 million and u...

1 year ago - GlobeNewsWire

First Light Acquisition Group, Inc. Announces Approval of Extension Amendment to Certificate of Incorporation

NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE: FLAG) (“FLAG”) today announced that its Board of Directors approved an extension of the date by which it has to c...

1 year ago - GlobeNewsWire

CORRECTION - First Light Acquisition Group, Inc. Transfers Listing to NYSE American LLC

NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- CORRECTED version from November 14, 2022 5:00 a.m. release. First Light Acquisition Group, Inc. (NYSE: FLAG) (“FLAG”), a special purpose acquisition company...

1 year ago - GlobeNewsWire

First Light Acquisition Group, Inc. Transfers Listing to NYSE American LLC

NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE: FLAG) (“FLAG”), a special purpose acquisition company, announced today that it will transfer its listing to the N...

1 year ago - GlobeNewsWire

FIRST LIGHT ACQUISITION GROUP, INC. Adjourns Special Meeting of Stockholders to September 13, 2022 at 10:00 am ET

NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE: FLAG) (“FLAG”) today announced that it convened and then adjourned, without conducting any other business, its v...

1 year ago - GlobeNewsWire

First Light Acquisition Group, Inc. Announces the Separate Trading of its shares of Class A Common Stock and Warrants, Commencing November 1, 2021

NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (the “Company”) announced that commencing November 1, 2021, holders of the units sold in the Company's initial public of...

2 years ago - GlobeNewsWire

First Light Acquisition Group, Inc. Completes $230 Million Initial Public Offering

NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (the “Company”), a blank check company formed for the purpose of entering into a combination with one or more businesse...

2 years ago - GlobeNewsWire